Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777811 | 0.83 | KMT2A (0.57) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL15883599 | 0.81 | KMT2A (0.59) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL1368324 | 0.80 | KMT2A (0.56) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL10343775 | 0.79 | KMT2A (0.57) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL29881989 | 0.77 | KMT2A (0.55) | SMN1; SMN2ALOX15HSD17B10MAPTKMT2A | |
| SCHEMBL11133586 | 0.77 | ABCB1 (0.61) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL11202217 | 0.75 | ABCB1 (0.60) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL2801970 | 0.73 | RAB9A (0.40) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL11200668 | 0.73 | ABCB1 (0.57) | RAB9ASMN1; SMN2ALOX15HSD17B10MAPT | |
| SCHEMBL15145150 | 0.73 | KMT2A (0.61) | SMN1; SMN2MAPTKMT2AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-08-17 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-09 | — | — | US | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2310014-B1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | UNIV HOLY GHOST DUQUESNE (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-01-16 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-11-05 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | GANGJEE ALEEM (US) | 2011-11-24 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982035-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2310014-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | Duquesne University of the Holy Ghost (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010006032-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082374-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | RAB9A 2923/4885SMN1; SMN2 4441/4885ALOX15 4396/4885 |
| US-20200017521-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | PLK1, AURKC, TOP1 | RAB9A 2964/4885SMN1; SMN2 2226/4885ALOX15 3865/4885 |
| US-20110288108-A1 | TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF | ABCG2, ABCC1, ABCB1 | RAB9A 2923/4885SMN1; SMN2 4441/4885ALOX15 4396/4885 |
| US-10676483-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | PLK1, AURKC, TOP1 | RAB9A 2964/4885SMN1; SMN2 2226/4885ALOX15 3865/4885 |
| US-11091500-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCB1, ABCG2 | RAB9A 2644/4885SMN1; SMN2 4266/4885ALOX15 4292/4885 |
| US-10464944-B2 | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCC1, ABCG2, TP53 | RAB9A 3128/4885SMN1; SMN2 4366/4885ALOX15 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.